However, recent findings highlight some limitations of NfL, such as its lack of specificity for MS compared to other neurodegenerative conditions, prompting ongoing research into complementary biomarkers that could offer more precise insights into disease mechanisms (7–9, 14). This evidence concerns the gene NEFL and myeloid sarcoma.